Reported Nov 9, Neurocrine Biosciences Provides Development Pipeline Update; Failed To Demonstrate Meaningful Reduction In Seizure Frequency; Failed to Meet Its Primary Endpoint In Patients With Anhedonia In Major Depressive Disorder
Benzinga Newsdesk - Nov 10, 2023, 11:16AM